Biogen Inc. (VIE:BIIB)
Austria · Delayed Price · Currency is EUR | Market Cap | 26.96B +72.1% |
| Revenue (ttm) | 8.62B +1.2% |
| Net Income | 1.19B -7.3% |
| EPS | 8.06 -8.1% |
| Shares Out | n/a |
| PE Ratio | 22.66 |
| Forward PE | 15.81 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1 |
| Open | 171.88 |
| Previous Close | 170.58 |
| Day's Range | 170.56 - 179.34 |
| 52-Week Range | 103.65 - 191.04 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe... [Read more]
Financial Performance
In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.
Financial numbers in USD Financial StatementsNews
Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting them to expert neurologist options nationwide. CHICAGO, July 16, 2026 /PRNewswire/ -- Synapticure, ...
Biogen appoints Michael Parini as chief legal officer
Biogen (BIIB) announced the appointment of Michael Parini as chief legal officer, effective August 3. Parini will serve as a member of Biogen’s executive committee and report to Christopher Viehbacher...
Biogen Appoints Michael J. Parini as Chief Legal Officer
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve ...
Biogen Transcript: Alzheimer’s Association International Conference (AAIC Meeting) 2026
Diranersen showed robust tau reduction and cognitive benefits in early Alzheimer's, with the 60 mg twice-yearly dose emerging as optimal. Safety was favorable, and high patient retention supports advancing to phase III, with long-term data and further regulatory engagement planned.
RBC says Biogen detailed Phase 2 results ‘leave more questions than answers’
After Biogen (BIIB) provided more detailed data from the Phase 2 CELIA study of diranersen in early Alzheimer’s disease during this morning at AAIC session, RBC Capital analyst Brian Abrahams…
Biogen to face questions on safety and dose response, says Stifel
After Biogen (BIIB) announced expanded data from the Phase 2 CELIA study evaluating diranersen in individuals with early Alzheimer’s disease, Stifel noted that the 60mg low dose of diranersen showed…
Eisai, Biogen announce presentation of results from real-world LEADER study
Eisai (ESAIY) and Biogen (BIIB) announced that results from the real-world Lecanemab in Early Alzheimer’s Disease Study show that nearly 83% of early Alzheimer’s disease patients enrolled in the study...
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Real-World Findings Support Long-Term Benefits of Continuous Treatment with LEQEMBI and Provide Important Insights into Treatment Experience Outside of a Clinical Trial Setting TOKYO and CAMBRIDGE, Ma...
Biogen announces expanded data from CELIA study evaluating diranersen
Biogen (BIIB) announced data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide therapy targeting tau, in individuals with early Alzheimer’s disease. The ...
Ionis says Biogen presents Phase 2 CELIA data at AAIC
Ionis Pharmaceuticals (IONS) announced that its partner, Biogen (BIIB), shared data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide therapy targeting t...
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
The lowest dose of Biogen's anti-tau Alzheimer's drug diranersen, which missed its primary goal in a midstage trial, reduced cognitive decline in five of six Alzheimer's assessment tools and signific...
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced data from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide (AS...
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in the U.S.) U.S. launch of LEQEMBI IQLIK as an initiation dose ...
Early subQ approval a fundamental positive for Biogen, says Jefferies
Jefferies reiterated a Buy rating and $255 price target on Biogen (BIIB) after the FDA approved Leqmbi’s subQ induction ahead of its August 24 PDUFA date. Although investors were already…
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
The U.S. FDA on Monday approved an at-home starting dose of Eisai's and Biogen's Alzheimer's drug, allowing some patients to begin therapy with injections administered by themselves or a caregiver.
Early subQ approval should help Biogen regain market share, says RBC
RBC Capital reiterated an Outperform rating and $242 price target on Biogen (BIIB) after the FDA approved Leqembi’s subQ formulation for treatment initiation roughly six weeks ahead of the August…
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer's Drug Study Details
Biogen stock receives a bullish upgrade based on expectations the market will cheer the company's detailed data on its experimental Alzheimer's drug.
Biogen price target raised to $201 from $196 at Wedbush
Wedbush raised the firm’s price target on Biogen (BIIB) to $201 from $196 and keeps a Neutral rating on the shares. The firm updated its model ahead of the Q2…
Biogen upgraded to Buy at Truist ahead of next week’s AAIC conference
As previously reported, Truist upgraded Biogen (BIIB) to Buy from Hold with a price target of $235, up from $190, ahead of the Phase 2 BIIB080 data presentation at AAIC…
Biogen upgraded to Buy from Hold at Truist
Truist upgraded Biogen (BIIB) to Buy from Hold with a $235 price target
Biogen, Eisai announce new data on efficacy, safety of LEQEMBI SC-AI
Eisai (ESAIY) and Biogen (BIIB) announced that new data presented at the Alzheimer’s Association International Conference, AAIC, 2026 in London support that the LEQEMBI subcutaneous autoinjector, SC-A...
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing convenience for patients and care partners TOKYO and CAMBRIDGE,...
Biogen price target lowered to $222 from $224 at Morgan Stanley
Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Biogen (BIIB) to $222 from $224 and keeps an Equal Weight rating on the shares. Biotech could benefit from…
Biogen price target raised to $217 from $203 at BofA
BofA raised the firm’s price target on Biogen (BIIB) to $217 from $203 and keeps a Neutral rating on the shares. Despite significant unmet need in Alzheimer’s disease, Leqembi’s commercial…